On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also ...
Viking Therapeutics (NasdaqCM:VKTX) has begun a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor agonist targeting obesity. The study marks the first human testing of VK3019 ...
Ligand Pharmaceuticals has accused Viking Therapeutics of breaching obligations under their licensing deal for thyroid hormone receptor beta (TRβ) therapies and moved to terminate the program. Viking ...
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
First, a bit of detail about these products and potential products. Lilly's drugs -- Mounjaro and Zepbound -- involve the molecule tirzepatide, which acts on glucagon-like peptide-1 (GLP-1) and ...
J.J. McCarthy is ready to roll as the Minnesota Vikings open their offseason program. "I'd consider him full. Really, no limitations," Vikings head coach Kevin O'Connell said on Monday. "I want to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results